Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease | Zendy

Marc S. Sabatine | Zendy; Gaetano Maria De Ferrari | Zendy; Robert P. Giugliano | Zendy; Kurt Huber | Zendy; Basil S. Lewis | Zendy; Jorge Ferreira | Zendy; Julia Kuder | Zendy; Sabina A. Murphy | Zendy; Stephen D. Wiviott | Zendy; Christopher E. Kurtz | Zendy; Narimon Honarpour | Zendy; Anthony Keech | Zendy; Peter Sever | Zendy; Terje R. Pedersen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease

Author(s) -

Marc S. Sabatine,

Gaetano Maria De Ferrari,

Robert P. Giugliano,

Kurt Huber,

Basil S. Lewis,

Jorge Ferreira,

Julia Kuder,

Sabina A. Murphy,

Stephen D. Wiviott,

Christopher E. Kurtz,

Narimon Honarpour,

Anthony Keech,

Peter Sever,

Terje R. Pedersen

Publication year - 2018

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.118.034309

Subject(s) - medicine , evolocumab , coronary artery disease , cardiology , cholesterol , apolipoprotein b , apolipoprotein a1

The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab significantly reduced major vascular events in patients with stable atherosclerotic cardiovascular disease, including patients with prior myocardial infarction (MI). Within the broad group of patients with prior MI, we hypothesized that readily ascertainable features would identify subsets who derive greater clinical risk reduction with evolocumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research